Pfizer beats profit estimates on cost cuts, heart drug sales

Reuters

Tue, Apr 29, 2025, 3:53 AM 1 min read

(Reuters) -U.S. drugmaker Pfizer reported first-quarter nett supra Wall Street estimates connected Tuesday, helped by cots cuts and better-than-expected income of its bosom illness drug, Vyndaqel.

On an adjusted basis, Pfizer earned 92 cents per stock successful the latest quarter, compared with analysts' expectations of 66 cents per share, according to LSEG data.

Investors are intimately watching for immoderate imaginable interaction connected Pfizer's vaccine concern and immoderate changes to recommendations for receiving flu, COVID and different shots nether the caller wellness caput Robert F Kennedy Jr., a longtime vaccine skeptic.

Pfizer and different drugmakers are besides astatine hazard of projected hefty duties connected commercialized partners specified arsenic China, which is simply a cardinal root of earthy ingredients and supplies for the pharmaceutical and aesculapian instrumentality industries.

Shares of the drugmaker, which person fallen 13.1% truthful acold this year, roseate 1% successful premarket trading.

It reported full gross of $13.70 cardinal for the archetypal quarter, compared with analysts' expectations of $13.91 billion, according to LSEG data.

(Reporting by Bhanvi Satija and Christy Santhosh successful Bengaluru and Michael Erman successful New York; Editing by Anil D'Silva)